Watch breaking news videos and read news updates about Bristol-Myers Squibb on FOXBusiness.com.
LATEST VIDEOS
Market experts Tom Hardesty and Brian Daley give tips for investing in today's market.
Government-Run Health Care Not Essential?
08/17/2009|Money for Breakfast
'The Agency Game' Author Bill Parker, Holtorf Medical Group Director Dr. Kent Holtorf and MRG Management Services President Michael Guarini on the Obama Administration backing off from its push for government-run health-care insurance.
What innovations can we expect as the nation seeks to reform its health-care program? Check out the full hour of FOXBusiness.com LIVE today.
Mario Gabelli weighs in on why he has faith in the return of profitability for U.S. auto makers.
Bristol - Myers Acquires Medarex for $2.1B
07/23/2009|FOX Business
Crystal Research Associates CEO Jeffrey Kraws on Bristol-Myers Squibb's acquisition of Medarex.
Regulatory Overhaul Another Sarbanes-Oxley?
06/18/2009|Opening Bell
Delphi Management President Scott Black on what needs to be done to fix President Obama's regulatory reform plan.
Where Mario Gabelli is putting his money
05/28/2009|Web Exclusive
GAMCO CEO Mario Gabelli talks to Dagen McDowell at the Morningstar Conference about where he's looking to invest and what the American car industry has to do to survive
In The Thick of The 2Q Earnings Season
04/08/2009|FOX Business
Former Barclays Capital Investment Manager Uri Man and Brookstone Partners Managing Partner Michael Toporek on this busy morning for second-quarter earnings such as Ford and Wyeth.
LATEST STORIES
FDA Warns Against Taking Plavix With Prilosec
| MarketWatch Pulse| Markets
as much as half. Plavix, the world's second best-selling drug, is co-marketed by Sanofi-Aventis and Bristol - Myers Squibb . Prilosec, also known as omeprazole, belongs to a group of widely-used antacids called PPIs, which also
Story|11/17/2009
Bristol-Myers to Divest Nutritional Division
FOXBusiness| Markets
FOXBusiness Bristol - Myers Squibb (BMY) announced plans on Monday ..... billion deal. The move would allow Bristol - Myers to focus more on its pharmaceutical ..... said is a goal for the company. Bristol - Myers took steps earlier this year to
Story|11/16/2009
Merck, Bristol-Myers Lead Drug Stocks Higher
| MarketWatch Pulse| Markets
Kennedy MarketWatch Pulse BOSTON -- Merck & Co. and Bristol - Myers Squibb led drugs stocks higher early Monday, joining the ..... Shares of Merck were up 3% at $34.24, while Bristol - Myers shares gained 4% to rest $23.98. Copyright
Story|11/16/2009
Bristol-Myers To Split Off Mead Johnson
| MarketWatch Pulse| Markets
By MarketWatch MarketWatch Pulse TOKYO -- Pharmaceutical giant Bristol - Myers Squibb Co . said Sunday it would split off its Mead Johnson Nutrition Co. as part of its divestment strategy to transition from a traditional
Story|11/15/2009
Mixed Results For Amgen’s Latest Vectibix Trial
FOXBusiness| Markets
cancer patients. Vectibix’s main competitor in the space is Erbitux, which is sold by Eli Lilly (LLY) and Bristol - Myers Squibb (BMY). Last year, Erbitux sales rose 8% to $739 million, while Vectibix sales dropped 36% to $108 million
Story|11/05/2009
Supreme Court Rejects Plavix Challenge
| FOXBusiness| Markets
thinner. The suit applied to Plavix, the blood thinner developed by Sanofi Aventis SA and co-marketed by Bristol - Myers Squibb Co . (BMY) Apotex had applied to market a generic version of the drug after the patent expired in 2003. France
Story|11/02/2009
Stock Sleuth Exposes Market Winners And Traps
| MarketWatch| Markets
Chevron Corp. (CVX) , Diamond Offshore Drilling (DO) , and VAALCO Energy (EGY) on the energy side, and Bristol - Myers Squibb Co . (BMY) , AmerisourceBergen (ABC) , Cubist Pharmaceuticals Inc. (CBST) and Questcor Pharmaceuticals Inc
Story|10/28/2009
Bristol-Myers Reports Lower Third-quarter Profit
| MarketWatch Pulse| Markets
Val Brickates Kennedy MarketWatch Pulse BOSTON -- Bristol - Myers Squibb said early Thursday that its third-quarter profit ..... cents a share, on revenue of $5.52 billion. Bristol - Myers said it now sees 2009 earnings coming in between
Story|10/22/2009
| MarketWatch| Markets
report a profit of 90 cents a share in the third quarter, according to analysts surveyed by Thomson Reuters. Bristol - Myers Squibb Co . (BMY) is expected to report earnings of 51 cents a share in the third quarter, according to analysts surveyed
Story|10/21/2009
EU Approves AstraZeneca, Bristol Diabetes Drug
| MarketWatch Pulse| Markets
Union regulators have approved AstraZeneca plc and Bristol - Myers Squibb 's diabetes drug Onglyza, the companies said Monday ..... down almost half a percentage point at $31.51. Bristol - Myers shares were trading down marginally at $22.22
Story|10/05/2009